S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
EXPLAINER: What's the effect of Russian oil price cap, ban?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
EXPLAINER: What's the effect of Russian oil price cap, ban?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
EXPLAINER: What's the effect of Russian oil price cap, ban?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
EXPLAINER: What's the effect of Russian oil price cap, ban?
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
NYSEAMERICAN:NBY

NovaBay Pharmaceuticals - NBY Stock Forecast, Price & News

$2.06
-0.06 (-2.82%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.04
$2.15
50-Day Range
N/A
52-Week Range
$2.00
$20.65
Volume
48,679 shs
Average Volume
27,655 shs
Market Capitalization
$3.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NovaBay Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of NovaBay Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$46,619 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.21) to ($0.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

NBY stock logo

About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Receive NBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NBY Stock News Headlines

See More Headlines
Receive NBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NBY Company Calendar

Last Earnings
11/11/2021
Today
12/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:NBY
Employees
22
Year Founded
N/A

Profitability

Net Income
$-11,030,000.00
Pretax Margin
-96.71%

Debt

Sales & Book Value

Annual Sales
$9.93 million
Book Value
$0.29 per share

Miscellaneous

Free Float
44,134,000
Market Cap
$3.84 million
Optionable
Not Optionable
Beta
3.47

Key Executives

  • Mr. Justin M. Hall Esq. (Age 44)
    Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director
    Comp: $400.52k
  • Mr. Andrew D. Jones (Age 51)
    CFO & Treasurer
    Comp: $367.02k
  • Dr. Audrey Kunin M.D. (Age 63)
    Chief Product Officer & Director
    Comp: $202.82k
  • Dr. Jeffrey Kunin M.D. (Age 59)
    Pres of DERMAdoctor













NBY Stock - Frequently Asked Questions

How have NBY shares performed in 2022?

NovaBay Pharmaceuticals' stock was trading at $10.5945 on January 1st, 2022. Since then, NBY shares have decreased by 80.5% and is now trading at $2.0650.
View the best growth stocks for 2022 here
.

Are investors shorting NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 37,300 shares, a decline of 96.6% from the October 31st total of 1,100,000 shares. Based on an average daily trading volume, of 55,400 shares, the days-to-cover ratio is presently 0.7 days.
View NovaBay Pharmaceuticals' Short Interest
.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) posted its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts' consensus estimates of ($1.40) by $0.35. The biopharmaceutical company had revenue of $1.84 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 96.77% and a negative trailing twelve-month return on equity of 67.65%.

When did NovaBay Pharmaceuticals' stock split?

NovaBay Pharmaceuticals's stock reverse split before market open on Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

Who are NovaBay Pharmaceuticals' major shareholders?

NovaBay Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Altium Capital Management LP (1.69%). Insiders that own company stock include Andrew D Jones, Audrey Kunin, Jeffrey Kunin, Jian Ping Fu, Justin Hall and Mijia Wu.
View institutional ownership trends
.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $2.07.

How much money does NovaBay Pharmaceuticals make?

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) has a market capitalization of $3.84 million and generates $9.93 million in revenue each year. The biopharmaceutical company earns $-11,030,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The official website for the company is novabay.com. The biopharmaceutical company can be reached via phone at (510) 899-8800, via email at jcain@lhai.com, or via fax at 510-474-1577.

This page (NYSEAMERICAN:NBY) was last updated on 12/3/2022 by MarketBeat.com Staff